C Corcept Therapeutics, Inc.
| Market Cap | $3.57B |
| P/E Ratio | 40.98 |
| Forward P/E | 20.90 |
| Dividend Yield | — |
| Beta | 0.31 |
| 52W Range | $28.66 - $117.33 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $0 | 0 | Sold |
Insider Trading
| Insider Name of the company insider who made the trade 39 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| BELANOFF JOSEPH KChief Executive Officer | Sale | 26,198 | $50.07 | $1.31M | 25 Mar 2026 | 25 Mar 2026 |
| Guyer WilliamChief Development Officer | Sale | 11,767 | $36.01 | $423.73K | 20 Mar 2026 | 20 Mar 2026 |
| BAKER G LEONARD JR | Buy | 24,218 | $33.56 | $812.84K | 17 Mar 2026 | 17 Mar 2026 |
| BAKER G LEONARD JR | Buy | 75,782 | $33.00 | $2.50M | 17 Mar 2026 | 17 Mar 2026 |
| Guyer WilliamChief Development Officer | Sale | 8,233 | $35.99 | $296.35K | 04 Mar 2026 | 06 Mar 2026 |
| William GuyerChief Development Officer | Sale | 8,233 | $35.99 | $296.35K | 04 Mar 2026 | 06 Mar 2026 |
| Guyer WilliamChief Development Officer | Sale | 20,000 | $40.87 | $817.33K | 03 Feb 2026 | 05 Feb 2026 |
| William GuyerChief Development Officer | Sale | 20,000 | $40.87 | $817.33K | 03 Feb 2026 | 05 Feb 2026 |
| Guyer WilliamChief Development Officer | Sale | 20,000 | $35.18 | $703.66K | 06 Jan 2026 | 08 Jan 2026 |
| Guyer WilliamChief Development Officer | Sale | 19,360 | $80.05 | $1.55M | 02 Dec 2025 | 03 Dec 2025 |
| Guyer WilliamChief Development Officer | Sale | 640 | $80.88 | $51.76K | 02 Dec 2025 | 03 Dec 2025 |
| William GuyerChief Development Officer | Sale | 640 | $80.88 | $51.76K | 02 Dec 2025 | 03 Dec 2025 |
| William GuyerChief Development Officer | Sale | 19,360 | $80.05 | $1.55M | 02 Dec 2025 | 03 Dec 2025 |
| BELANOFF JOSEPH KChief Executive Officer | Sale | 40,000 | $79.77 | $3.19M | 01 Dec 2025 | 03 Dec 2025 |
| Lyon Joseph DouglasSee Remarks | Sale | 5,000 | $79.53 | $397.63K | 01 Dec 2025 | 03 Dec 2025 |
| Maduck SeanSee Remarks | Sale | 20,000 | $79.52 | $1.59M | 01 Dec 2025 | 03 Dec 2025 |
| Joseph Douglas LyonChief Accounting & Technology Officer | Sale | 5,000 | $79.53 | $397.63K | 01 Dec 2025 | 03 Dec 2025 |
| Sean MaduckPresident, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. | Sale | 20,000 | $79.52 | $1.59M | 01 Dec 2025 | 03 Dec 2025 |
| Joseph K BelanoffChief Executive Officer | Sale | 40,000 | $79.77 | $3.19M | 01 Dec 2025 | 03 Dec 2025 |
| Guyer WilliamChief Development Officer | Sale | 4,500 | $80.90 | $364.07K | 25 Nov 2025 | 26 Nov 2025 |
| William GuyerChief Development Officer | Sale | 4,500 | $80.90 | $364.07K | 25 Nov 2025 | 26 Nov 2025 |
| Guyer WilliamChief Development Officer | Sale | 13,164 | $75.64 | $995.68K | 05 Nov 2025 | 07 Nov 2025 |
| BELANOFF JOSEPH KChief Executive Officer | Sale | 3,590 | $75.98 | $272.76K | 05 Nov 2025 | 05 Nov 2025 |
| BELANOFF JOSEPH KChief Executive Officer | Sale | 10,837 | $75.14 | $814.26K | 05 Nov 2025 | 05 Nov 2025 |
| Guyer WilliamChief Development Officer | Sale | 300 | $76.28 | $22.88K | 05 Nov 2025 | 07 Nov 2025 |
| Guyer WilliamChief Development Officer | Sale | 6,536 | $74.75 | $488.56K | 05 Nov 2025 | 07 Nov 2025 |
| BELANOFF JOSEPH KChief Executive Officer | Sale | 14,355 | $74.20 | $1.07M | 05 Nov 2025 | 05 Nov 2025 |
| Joseph K BelanoffChief Executive Officer | Sale | 14,355 | $74.20 | $1.07M | 05 Nov 2025 | 05 Nov 2025 |
| Joseph K BelanoffChief Executive Officer | Sale | 3,590 | $75.98 | $272.76K | 05 Nov 2025 | 05 Nov 2025 |
| Joseph K BelanoffChief Executive Officer | Sale | 10,837 | $75.14 | $814.26K | 05 Nov 2025 | 05 Nov 2025 |
| BELANOFF JOSEPH KChief Executive Officer | Sale | 11,218 | $74.08 | $831.01K | 03 Nov 2025 | 05 Nov 2025 |
| Lyon Joseph DouglasSee Remarks | Sale | 5,000 | $73.65 | $368.24K | 03 Nov 2025 | 05 Nov 2025 |
| Maduck SeanSee Remarks | Sale | 20,000 | $73.99 | $1.48M | 03 Nov 2025 | 05 Nov 2025 |
| Joseph Douglas LyonChief Accounting & Technology Officer | Sale | 5,000 | $73.65 | $368.24K | 03 Nov 2025 | 05 Nov 2025 |
| Joseph K BelanoffChief Executive Officer | Sale | 11,218 | $74.08 | $831.01K | 03 Nov 2025 | 05 Nov 2025 |
| Sean MaduckPresident, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. | Sale | 20,000 | $73.99 | $1.48M | 03 Nov 2025 | 05 Nov 2025 |
| Swisher Daniel N JR | Sale | 2,200 | $87.54 | $192.59K | 10 Oct 2025 | 15 Oct 2025 |
| Daniel N Swisher JRDirector | Sale | 2,200 | $87.54 | $192.59K | 10 Oct 2025 | 15 Oct 2025 |
| Guyer WilliamChief Development Officer | Sale | 20,000 | $89.94 | $1.80M | 07 Oct 2025 | 09 Oct 2025 |
Frequently Asked Questions
What is CORT stock price today?
Corcept Therapeutics, Inc. (CORT) is currently trading at $33.61. The stock has a 52-week range of $28.66 to $117.33 and a market capitalization of $3.57B.
Is CORT a good stock to buy in 2026?
Corcept Therapeutics, Inc. has a P/E ratio of 41.0 (forward P/E: 20.9), a dividend yield of none, and 1-year performance of -40.5%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling CORT stock?
There have been 39 insider transactions for CORT in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has CORT stock performed over the past year?
Corcept Therapeutics, Inc. (CORT) has returned -40.5% over the past 12 months. The stock traded between $28.66 and $117.33 during this period, and is currently at $33.61.
Which hedge funds own CORT (Corcept Therapeutics, Inc.)?
1 tracked hedge funds currently hold CORT in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is CORT's market cap and valuation?
Corcept Therapeutics, Inc. (CORT) has a market capitalization of $3.57B. The trailing P/E ratio is 41.0 and forward P/E is 20.9. The stock is classified in the Healthcare sector.
What is CORT's revenue and profitability?
Corcept Therapeutics, Inc. reported revenue of $761.41M with net income of $98.17M and a profit margin of 0.13%. The stock has a beta of 0.31.
What sector is CORT in and who are its biggest institutional holders?
Corcept Therapeutics, Inc. (CORT) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.